Boehringer Ingelheim Presents New idarucizumab (Praxbind®) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran

Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Pradaxa | Research